Products
Baminercept Biosimilar Fusion Protein (LTA) for Research
Pre-Made Baminercept Biosimilar, Fusion Protein targeting LTA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LT/TNFB/TNFSF1/TNLG1E is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Baminercept is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig), for the treatment of primary Sjögren's syndrome (SS). Primary Sjögren’s syndrome (pSjS) is characterized by chronic inflammation of the lacrimal and salivary glands, as well as frequent extra glandular involvement and increased risk of B cell lymphoma. Several lines of evidence implicate the lymphotoxin (LT) pathway in the pathogenesis of this disease. Baminercept inhibits the LT pathway, which is important in lymphoid tissue organization and chronic inflammation.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-749-1mg | 1mg | 3090 |
| GMP-Bios-INN-749-10mg | 10mg | |
| GMP-Bios-INN-749-100mg | 100mg | |
| GMP-Bios-INN-749-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Baminercept Biosimilar, Fusion Protein targeting LTA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LT/TNFB/TNFSF1/TNLG1E |
| INN Name | Baminercept |
| Target | LTA |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [LTBR (lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily (TNFR) member 3, TNFCR)]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [LTBR (lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily (TNFR) member 3, TNFCR)]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Biogen, Inc. (Cambridge MA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - LTA
1. Protein Lymphotoxin-alpha
2. Gene LTA
3. Organism Homo sapiens (Human)
Function
Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM (PubMed:9462508).
In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and is cytotoxic for a wide range of tumor cells in vitro and in vivo.
